54P - Telomere length, telomerase activity and DAPK1 expression, new markers for prognosis in non-small cell lung cancer

Date 28 March 2014
Event ELCC 2014
Session Lunch and poster display session
Topics Lung and other Thoracic Tumours
Translational Research
Presenter Tamara Fernández
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors T. Fernández1, I. Pascua1, C. de Juan1, J. Head1, A. Gómez2, J.R. Jarabo2, E. Fernández3, M. Benito4, P. Iniesta1, F. Hernando2
  • 1Biochemistry And Molecular Biology Ii, Faculty of Pharmacy, Complutense University and Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), 28040 - Madrid/ES
  • 2Servicios De Cirugía General Y Torácica And Instituto De Investigación Sanitaria Del Hospital Clínico San Carlos (idissc), Hospital Clínico San Carlos, 28040 - Madrid/ES
  • 3Thoracic Surgery, Hospital Clínico San Carlos, 28040 - Madrid/ES
  • 4Biochemistry And Molecular Biology Ii., Faculty of Pharmacy, Complutense University and Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), 28040 - Madrid/ES

Abstract

The essential role that telomeres and telomerase play in cancer makes them an important objective in the field of molecular oncology. Our aim in this work consists of analysing the prognostic role of telomere length and telomerase activity in non-small cell lung cancers (NSCLCs). Moreover, considering previous results[1] and its potential as an important downstream target of Src kinase inhibitors (bosutinib, dasatinib)[2], we evaluated the expression of death-associated protein kinase 1 (DAPK1), in relation to telomere status. [1] Oncology 82, (2012). [2] FEBS Journal 277, (2010).